Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

The purpose of this research is to see if Loncastuximab Tesirine in combination with Rituximab will result in higher complete response rate when given to treat follicular lymphoma.

Trial Details

NCT ID
NCT04998669
Phase
PHASE2
Sponsor
Juan P. Alderuccio, MD
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Loncastuximab tesirine
  • Rituximab
Locations (sample)
  • Fort Myers, Florida, United States|26.62168,-81.84059
  • Miami, Florida, United States|25.77427,-80.19366
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • New Brunswick, New Jersey, United States|40.48622,-74.45182
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Men and women ≥ 18 years of age.
  • Patients must have histologic confirmation of Follicular Lymphoma (FL) (grade 1, 2 and 3A). Note: Participants who have received previous CD19-dire…
  • Patients with relapsed or refractory FL previously treated with ≥1 line of systemic therapy having ≥ 1 Groupe d'Etude des Lymphomes (GELF) criteria…
  • Baseline FDG-PET/CT scans must demonstrate positive lesions compatible with CT defined anatomical tumor sites. Patients should have at least one me…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →